Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Nick Thatcher, Kevin Carroll, Alex Y. Chang et al.|The Lancet|2005Cited by 2.1k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal CancerMarc Peeters, Jennifer Gansert, Yevhen Hotko et al.|Journal of Clinical Oncology|2010Cited by 1k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Federico Nasroulah, Takayuki Yoshino et al.|The Lancet Oncology|2015Cited by 954
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerFred R. Hirsch, Brian R. Holloway, Marileila Varella‐Garcia et al.|Journal of Clinical Oncology|2006Cited by 702
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227Julie R. Brahmer, Suresh S. Ramalingam, Jong-Seok Lee et al.|Journal of Clinical Oncology|2022Cited by 375